[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou BlueHorse Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,62,84,102,122,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627115","phase-2-a-phase-ii-trial-of-lm103-for-adjuvant-treatment-in-patients-with-non-small-cell-lung-cancer-100627115",false,"NCT07444437","A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations","Inclusion Criteria:\n\n* At the date of signing Informed Consent Form (ICF), 18 \\~75 years old, male or female;\n* Expected survival time \\>3 months;\n* ECOG performance status 0-1;\n* Pathologically diagnosed as resectable non-small cell lung cancer:\n\n  1. Received preoperative neoadjuvant therapy (including PD-1 antibody);\n  2. Screening criteria:\n\n  i. Driver gene mutations was negative; ii. No disease recurrence (including local recurrence) after surgery; iii. Expected to complete standard adjuvant therapy.\n* Patients have lesions that can be used for surgical resection or biopsy puncture;\n* Patients have sufficient hematology and organ functions;\n* Voluntarily sign a written informed consent form (ICF).\n\nExclusion Criteria:\n\n* A history of other malignant tumors within the past 5 years, excluding malignant tumors that can be expected to heal after treatment (including but not limited to well-treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery);\n* Adverse reactions caused by previous treatments have not been recovered to grade ≤1 (CTCAE V6.0) (excluding alopecia and neurotoxicity, and hypothyroidism, adrenal insufficiency and hypopituitarism that cannot be restored to grade 2 as determined by the investigators for a long time);\n* Any immune-related adverse reaction (irAE) with a severity level greater than grade 3 that has occurred during any previous immunotherapy and has been permanently discontinued;\n* Have received vaccination within two months prior to signing the ICF, or plan to receive vaccination during the study;\n* Have received TIL cell therapy, allogeneic T cell therapy or NK cell therapy within 6 months prior to signing the ICF;\n* Have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation in the past;\n* Suffering from or suspected of having an active autoimmune disease;\n* Suffering from a large amount of pleural effusion or ascites with clinical symptoms or requiring symptomatic treatment;\n* Patients with current or previous irreversible interstitial lung disease;\n* Suffering from serious cardiovascular and cerebrovascular diseases;\n* Suffering from an active infection that requires systemic treatment;\n* Suffering from infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS;\n* Patients with esophageal or gastric varices requiring immediate intervention (such as ligation or sclerotherapy), or those with a higher risk of bleeding as recommended by the investigator or gastroenterologist or hepatologist, evidence of portal hypertension (including splenomegaly found in imaging examinations), or a history of variceal bleeding must undergo endoscopic assessment within 3 months before enrollment;\n* Uncontrolled metabolic disorders, such as diabetes, or other non-malignant organ or systemic diseases or secondary reactions to cancer, can lead to higher medical risks and\u002For uncertainties in survival assessment;\n* Those who are known to be allergic to any component of the investigational drug and the LM103 product formula;\n* Women who are pregnant or breastfeeding;\n* As determined by the investigators, there are other severe, acute or chronic medical diseases, mental disorders or laboratory abnormalities that may increase the risks related to participation in the study or may interfere with the interpretation of the study results.","ALL","18 Years","75 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.",[27],"Non-Small Cell Lung Cancer","RECRUITING","2026-05-10",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":32},"2026-02-26",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Suzhou BlueHorse Therapeutics Co., Ltd.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":60,"locationsCount":61},"100616836","phase-2-a-phase-ii-trial-of-lm103-in-advanced-melanoma-100616836","NCT07310784","A Phase II Trial of LM103 in Advanced Melanoma","A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma","Inclusion Criteria:\n\n* At the date of signing Informed Consent Form (ICF), 18 \\~75 years old, male or female;\n* Expected survival time \\>3 months;\n* ECOG performance status 0-1;\n* Patients with unresectable recurrent\u002Fmetastatic melanoma (excluding uveal melanoma) who have failed at least two lines of standard treatment: • Patients need to have failed or be intolerant to PD-1 antibody treatment; • If the BRAF V600 mutation is positive, treatment with BRAF±MEK inhibitors must fail; • If the NRAS mutation is positive, treatment with Tunlametinib must fail;\n* Patients have lesions that can be used for surgical resection or biopsy puncture;\n* Even after tumor tissue resection\u002Fbiopsy puncture, there should still be at least one measurable lesion (according to RECIST1.1);\n* Patients have sufficient hematology and organ functions;\n* Voluntarily sign a written informed consent form (ICF).\n\nExclusion Criteria:\n\n* A history of other malignant tumors within the past 5 years, excluding malignant tumors that can be expected to heal after treatment (including but not limited to well-treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery);\n* Adverse reactions caused by previous treatments have not been recovered to grade ≤1(CTCAE V5.0) (excluding the laboratory tests from the inclusion criteria, alopecia and neurotoxicity, and hypothyroidism, adrenal insufficiency and hypopituitarism that cannot be restored to grade 2 as determined by the investigators for a long time);\n* Any immune-related adverse reaction (irAE) with a severity level greater than grade 3 that has occurred during any previous immunotherapy and has been permanently discontinued;\n* Have received vaccination within two months prior to tumor tissue procurement surgery, or plan to receive vaccination during the study;\n* Have received TIL cell therapy, allogeneic T cell therapy or NK cell therapy within 6 months prior to signing the ICF;\n* Have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation in the past;\n* Suffering from central nervous system metastases and\u002For cancerous meningitis. Patients who have received brain metastasis treatment and whose conditions have been stable for at least 6 months, and there is no evidence of new or expanded brain metastases may consider participating in this study;\n* Suffering from or suspected of having an active autoimmune disease;\n* Suffering from a large amount of pleural effusion or ascites with clinical symptoms or requiring symptomatic treatment;\n* Patients with current or previous irreversible interstitial lung disease;\n* Suffering from serious cardiovascular and cerebrovascular diseases;\n* Suffering from an active infection that requires systemic treatment;\n* Suffering from infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS;\n* Patients with esophageal or gastric varices requiring immediate intervention (such as ligation or sclerotherapy), or those with a higher risk of bleeding as recommended by the investigator or gastroenterologist or hepatologist, evidence of portal hypertension (including splenomegaly found in imaging examinations), or a history of variceal bleeding must undergo endoscopic assessment within 3 months before enrollment;\n* Uncontrolled metabolic disorders, such as diabetes, or other non-malignant organ or systemic diseases or secondary reactions to cancer, can lead to higher medical risks and\u002For uncertainties in survival assessment;\n* Those who are known to be allergic to any component of the investigational drug and the LM103 product formula;\n* Women who are pregnant or breastfeeding;\n* As determined by the investigators, there are other severe, acute or chronic medical diseases, mental disorders or laboratory abnormalities that may increase the risks related to participation in the study or may interfere with the interpretation of the study results.",{"count":49,"type":21},92,[24],"A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.",[53],"Advanced Melanoma","2026-05-09",{"date":56,"type":32},"2026-05-12",{"date":58,"type":32},"2025-12-16",{"date":36,"type":21},{"name":38,"class":39},13,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100569701","early-phase-1-an-exploratory-clinical-study-to-evaluate-the-safety-tolerability-immune-response-and-preliminary-efficacy-of-lm103-injection-in-combination-with-pd-1-in-patients-with-advanced-solid-tumours-100569701","NCT06697665","An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n1. The expected survival time is not less than 3 months.\n2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.\n3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, cervical cancer\u002Fovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.\n4. The patient has lesions that can be used for surgical resection (\\>1.5 cm3) or biopsy puncture (no less than 6 lesions) for LM103 manufacturing.\n5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).\n6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.\n\nExclusion Criteria:\n\n1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).\n2. LM103 received systematic therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.\n3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).\n4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.",{"count":69,"type":21},10,[71],"EARLY_PHASE1","This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours. The research treatment includes LM103 injection, IL-2 therapy, PD-1 therapy,fludarabine and cyclophosphamide.",[74],"Solid Cancer","2024-11-17",{"date":77,"type":32},"2024-11-20",{"date":79,"type":32},"2024-01-23",{"date":81,"type":21},"2027-06",{"name":38,"class":39},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":83},"100569549","early-phase-1-an-investigator-initiated-clinical-study-of-lm303-injection-for-the-treatment-of-advanced-solid-tumours-100569549","NCT06695689","An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours","Inclusion Criteria:\n\n1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment;\n2. The patient has residual lesions that can be used for surgical resection (\\>1.5cm3) or biopsy (\\>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation;\n3. Laboratory inspection index requirements:\n\n   * Blood routine: lymphocyte ratio \\> 20%; neutrophil count \\> 1.0 × 10\\^9\u002FL; white blood cells \\> 3.0 × 10\\^9\u002FL; platelets \\> 100 × 10\\^9\u002FL; hemoglobin \\> 80 g\u002F L;\n   * Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ upper limit of normal x 2.5, if there is liver metastasis ≤ upper limit of normal x 5; alkaline phosphatase (ALP) ≤ upper limit of normal x 2.5; total gallbladder Red pigment (TBIL)≤normal upper limit×1.5;\n   * Renal function: urea ≤ upper limit of normal × 1.5; creatinine (Cr) ≤ upper limit of normal × 1.5;\n4. Left ventricular ejection fraction (LVEF) ≥ 50%;\n5. ECOG physical condition is 0 or 1;\n6. The expected survival time is more than 3 months;\n\nExclusion Criteria:\n\n1. Suffering from active or previous autoimmune diseases ;\n2. Severe liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and hematopoietic dysfunction;\n3. Combined with severe infection or persistent infection and cannot be effectively controlled;\n4. Central nervous system metastasis and\u002For cancerous meningitis;\n5. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;\n6. Requires systemic steroid therapy;\n7. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb); positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis;",{"count":69,"type":21},[71],"This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM303 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.",[94],"Solid Tumor",{"date":96,"type":32},"2024-11-19",{"date":98,"type":32},"2024-10-17",{"date":100,"type":21},"2027-10",{"name":38,"class":39},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100513908","early-phase-1-a-clinical-study-on-lm103-injection-for-the-treatment-of-advanced-solid-tumors-100513908","NCT05971589","A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors","An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. The expected survival time is not less than 6 months.\n2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.\n3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, head and neck squamous cell cancer, soft tissue sarcoma and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.\n4. The patient has lesions that can be used for surgical resection (\\>1.5 cm\\^3) or biopsy puncture (no less than 6 lesions) for TILs collection.\n5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).\n6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.\n\nExclusion Criteria:\n\n1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).\n2. LM103 received systematic Sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.\n3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).\n4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.",{"count":40,"type":21},[71],"This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients. The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.",[94],"NOT_YET_RECRUITING","2023-07-25",{"date":116,"type":32},"2023-08-02",{"date":118,"type":21},"2023-08",{"date":120,"type":21},"2026-08",{"name":38,"class":39},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":107,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":136,"locationsCount":4},"100513907","early-phase-1-a-clinical-study-on-tils-for-the-treatment-of-advanced-solid-tumors-100513907","NCT05971576","A Clinical Study on TILs for the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. The expected survival time is not less than 3 months.\n2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.\n3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, cervical cancer\u002Fovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.\n4. The patient has lesions that can be used for surgical resection (\\>1.5 cm3) or biopsy puncture (no less than 6 lesions) for TILs collection.\n5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).\n6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.\n\nExclusion Criteria:\n\n1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).\n2. LM103 received systematic Sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.\n3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).\n4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.",{"count":129,"type":21},20,[71],"This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.",[94],{"date":116,"type":32},{"date":118,"type":21},{"date":120,"type":21},{"name":38,"class":39},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":83},"100467416","phase-1-a-clinical-study-of-lm103-injection-in-the-treatment-of-advanced-solid-tumors-100467416","NCT05366478","A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors","A Single-Arm, Open-Label, Exploratory Study to Evaluate Safety and Efficacy of LM103 Injection in the Treatment of Advanced Solid Tumors",{"count":144,"type":21},15,[146],"PHASE1","This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.",[149,150,151],"Melanoma","Non Small Cell Lung Cancer","Cervical Carcinoma","2022-08-01",{"date":154,"type":32},"2022-08-02",{"date":156,"type":32},"2022-05-30",{"date":158,"type":21},"2029-05-30",{"name":38,"class":39},""]